Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma	Recruiting	Phase 2	2026-04-23		NCT06340711

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Merck Sharp & Dohme LLC	650
Oncolys BioPharma Inc	1
Weill Medical College of Cornell University	276

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	United States	47
Weill Cornell Medicine/NewYork-Presbyterian Hospital	New York	United States	7

Clinical trials